生物技术公司Azitra Inc(简称Azitra)近日收到纽交所美国板块发出的不合规通知。该通知指出,Azitra未能满足交易所的特定上市标准。作为回应,Azitra已根据纽交所美国板块上市规则第610(B)条的规定,发布了公开声明。此举旨在向投资者及时披露相关监管动态,确保信息透明度。
生物技术公司Azitra Inc(简称Azitra)近日收到纽交所美国板块发出的不合规通知。该通知指出,Azitra未能满足交易所的特定上市标准。作为回应,Azitra已根据纽交所美国板块上市规则第610(B)条的规定,发布了公开声明。此举旨在向投资者及时披露相关监管动态,确保信息透明度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.